Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On December 9, 2016, at 3:05 p.m. Greenwich Mean Time, James D.
Berry, MD, MPH of the Department of Neurology at Massachusetts
General Hospital, will present clinical data from Brainstorm Cell
Therapeutics Inc.s (the Company) NurOwn Phase 2 Trial, at the
27th International Symposium on ALS/MND. Notice of
this event was previously given on December 5, 2016 via press
release, a copy of which is furnished as Exhibit 99.1 to this
Form 8-K.
The slides that will be used for the presentation will be posted
on the Companys website (www.brainstorm-cell.com) prior to the
conference call. A copy of the slides is furnished as Exhibit
99.2 to this Current Report on Form 8-K.
This information shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated December 5, 2016 | |
| 99.2 | Presentation slides dated December 9, 2016 |
About Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Recent Trading Information
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) closed its last trading session down -0.04 at 2.16 with 44,552 shares trading hands.
